Skip to main content
Top
Published in: Rheumatology International 1/2013

01-01-2013 | Short Communication

Herpes zoster infection, vaccination and immunocompromised rheumatology patients

Authors: Mortimer B. O’Connor, Mark J. Phelan

Published in: Rheumatology International | Issue 1/2013

Login to get access

Abstract

Varicella is a self-limiting and relatively mild disease of childhood, although it is frequently more severe and complicated among the immunocompromised rheumatology patients on immunomodulator therapies. In addition, future reactivation of the dormant virus in dorsal root ganglia may cause herpes zoster infection, which can be very debilitating. In this manuscript, we discuss the nature of this infection along with its potential vaccine especially among rheumatology patients.
Literature
1.
go back to reference Quinlivan M, Hawrami K, Barrett-Muir W, Aaby P, Arvin A, Chow VT et al (2002) The molecular epidemiology of varicella-zoster virus: evidence for geographic segregation. J Infect Dis 186(7):888–894PubMedCrossRef Quinlivan M, Hawrami K, Barrett-Muir W, Aaby P, Arvin A, Chow VT et al (2002) The molecular epidemiology of varicella-zoster virus: evidence for geographic segregation. J Infect Dis 186(7):888–894PubMedCrossRef
2.
go back to reference Takahashi M, Okuno Y, Otsuka T, Osame J, Takamizawa A (1975) Development of a live attenuated varicella vaccine. Biken J 18(1):25–33PubMed Takahashi M, Okuno Y, Otsuka T, Osame J, Takamizawa A (1975) Development of a live attenuated varicella vaccine. Biken J 18(1):25–33PubMed
3.
go back to reference American Academy of Pediatrics Committee on Infectious Diseases (1995) Recommendations for the use of live attenuated varicella vaccine. Pediatrics 95(5):791–796 American Academy of Pediatrics Committee on Infectious Diseases (1995) Recommendations for the use of live attenuated varicella vaccine. Pediatrics 95(5):791–796
4.
go back to reference Thiry N, Beutels P, Van Damme P, Van Doorslaer E (2003) Economic evaluations of varicella vaccination programmes: a review of the literature. Pharmacoeconomics 21(1):13–38PubMedCrossRef Thiry N, Beutels P, Van Damme P, Van Doorslaer E (2003) Economic evaluations of varicella vaccination programmes: a review of the literature. Pharmacoeconomics 21(1):13–38PubMedCrossRef
5.
go back to reference Thomas SL, Wheeler JG, Hall AJ (2002) Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 360(9334):678–682PubMedCrossRef Thomas SL, Wheeler JG, Hall AJ (2002) Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 360(9334):678–682PubMedCrossRef
6.
go back to reference Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G (2000) Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol Infect 125(3):651–669PubMedCrossRef Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G (2000) Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol Infect 125(3):651–669PubMedCrossRef
7.
go back to reference Brisson M, Edmunds WJ, Gay NJ (2003) Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV. J Med Virol 70(Suppl 1):S31–S37PubMedCrossRef Brisson M, Edmunds WJ, Gay NJ (2003) Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV. J Med Virol 70(Suppl 1):S31–S37PubMedCrossRef
Metadata
Title
Herpes zoster infection, vaccination and immunocompromised rheumatology patients
Authors
Mortimer B. O’Connor
Mark J. Phelan
Publication date
01-01-2013
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 1/2013
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-011-2155-9

Other articles of this Issue 1/2013

Rheumatology International 1/2013 Go to the issue